NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd.
- Market cap
- $120.87K
Your view on NRSNW
Overview
What the company does, where it operates, and who runs it.
About NeuroSense Therapeutics Ltd.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alon Ben-Noon
- Headquarters
- Medinat ha-Yehudim Street 85, Herzliya, TA, IL
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Alon Ben-Noon
- Headquarters
- Medinat ha-Yehudim Street 85, Herzliya, TA, IL
NeuroSense Therapeutics Ltd. is an Israeli clinical-stage biotechnology firm dedicated to pioneering novel therapies for severe neurodegenerative conditions. Its most advanced investigational asset is PrimeC, an innovative oral compound specifically engineered to address amyotrophic lateral sclerosis (ALS).
Beyond its lead program, the company boasts a preclinical pipeline featuring StabiliC, aimed at Parkinson's disease, and CogniC, targeting Alzheimer's disease. Established in Herzliya, Israel, in 2017, NeuroSense Therapeutics continues to advance its therapeutic initiatives.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for NeuroSense Therapeutics Ltd.. Starting points for NeuroSense Therapeutics Ltd.: EPS -$6.86, beta 1.60 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for NeuroSense Therapeutics Ltd.. Trailing twelve-month EPS for NeuroSense Therapeutics Ltd. stands at -$6.86. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for NeuroSense Therapeutics Ltd.. NeuroSense Therapeutics Ltd. has reported as a listed company since 2021. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| BETR.CNBetterLife Pharma Inc. | Healthcare | CNQ | — | ||
| BETRFBetterLife Pharma Inc. | Healthcare | OTC | $6.4M | ||
| BHVNBiohaven Ltd. | Healthcare | NYSE | $1.9B | ||
| BICTFBiocure Technology Inc. | Healthcare | OTC | $379,088 | ||
| BIOABioAge Labs, Inc. | Healthcare | NASDAQ | $161.1M | ||
| BIOAFBioasis Technologies Inc. | Healthcare | OTC | $15,883 | ||
| BIORQBiora Therapeutics, Inc. | Healthcare | PNK | — | ||
| BIT.AXBiotron Limited | Healthcare | ASX | — | ||
| BITRFBiotron Limited | Healthcare | OTC | $29.2M | ||
| BIVIBioVie Inc. | Healthcare | NASDAQ | $8.6M | ||
| BIXTBioxytran, Inc. | Healthcare | OTC | $3.6M | ||
| BLAB.CNBritannia Life Sciences Inc. | Healthcare | CNQ | $13.0M | ||
Institutional Ownership
Which funds and firms own the stock.
About this section
Which institutions hold NeuroSense Therapeutics Ltd., and how their positions are changing. At a $120,867 market value, institutional positions materially move NeuroSense Therapeutics Ltd.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings.
Insider Trading
Recent buying and selling by company executives.
About this section
Buying and selling by NeuroSense Therapeutics Ltd. executives and directors. Shares of NeuroSense Therapeutics Ltd. have traded between $0.06 and $0.30 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned.
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for NeuroSense Therapeutics Ltd.. Coverage tracks NeuroSense Therapeutics Ltd. within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of NeuroSense Therapeutics Ltd.